Device-handling study of a novel breath-actuated inhaler, Synchrobreathe®, versus a pMDI

Effectiveness and safety of salmeterol/fluticasone fixed-dose combination delivered through Synchrobreathe® in patients with asthma: the real-world EVOLVE study

“…Overall, Synchrobreathe ® was preferred and rated highly over the pMDI by the study participants. 11 In another randomized study, it was demonstrated that BAIs were correctly used by over 90% of patients. 22 A similar preference for BAIs over pMDIs was also seen in an observational study that assessed the adequacy of the inhaler technique and patient preferences in the elderly.…”

“…BAIs show better lung deposition of the medication than pMDIs in patients with poor technique and coordination. 11 Recently, a BAI device with a dose counter, the Synchrobreathe ® , has been introduced with salmeterol/fluticasone (SFC) as active drugs. The device is actuated at low inspiratory flow rates of approximately 27–30 L/min.…”

“…The device is actuated at low inspiratory flow rates of approximately 27–30 L/min. 11 When selecting the inhalation device for a patient, in addition to drug safety and efficacy, the patient’s preference and acceptance of the device, ease of training, and device usability are important considerations for the physician. 12 We conducted a real-world study to evaluate the efficacy, safety, and usability of the BAI, Synchrobreathe ® , containing SFC in patients with persistent asthma in India.…”

Dispositivos de inhalación para asma y EPOC: una revisión de la literatura

“…BAI facilitate the inhalation technique because no coordination is needed; also, these devices are portable and compact, which is an advantage related to patient preference. However, one disadvantage is that in case of severe stages of disease and exacerbation episodes, the inspiratory flow needed for the medication to be triggered could not be enough (52)(53)(54). It is important to highlight that the Synchrobreathe ® device requires the lowest inspiratory flow compared to all other devices available in the market.…”

“…It is important to highlight that the Synchrobreathe ® device requires the lowest inspiratory flow compared to all other devices available in the market. In an open-label, prospective study performed by Balamurugan et al (53), 421 patients with asthma and COPD were assessed for device handling, ease of use and perception regarding Synchrobreathe ® vs pMDI. These patients were also evaluated for the ability to use the device without errors at the first attempt, patient preference, total number of training sessions, and number of attempts to perform correct technique on day 1 and day 14.…”